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ABSTRACT: A mechanochemical procedure was developed to
obtain PZ-1361, a potent and selective 5-HT7 receptor antagonist,
with antidepressant properties in rodents. The elaborated protocol
offered several advantages over classical batch synthesis, including
improvement of the overall yield (from 34% to 64%), reduction of
reaction time (from 60 to 5.5 h), limitation of the use of toxic
solvents, and the formation of byproducts. This approach
represents a rare example of the synthesis of biologically active
compounds exclusively performed using mechanochemical reac-
tions.
Synthetic organic chemistry represents a key component ofmany drug discovery programs. In the last decades,
different techniques have been developed, for example,
microwave-assisted organic chemistry and flow chemistry,
which might reduce the time required to generate compound
libraries for biological screening or might ensure more efficient
production of active pharmaceutical ingredients (APIs).1−4
Recently, mechanochemical synthesis has also been recognized
as an innovative methodology,5 with a wide range of practical
applications in both academic and industrial research. In
particular, mechanochemistry has been used to produce
various families of compounds.6−10 The primary driving
force underlying the rediscovery of mechanochemistry is
green chemistry,11−13 in particular, the need of chemical and
pharmaceutical industries for the development of more
sustainable synthetic protocols characterized by the energy
efficiency of chemical transformations and reduction of solvent
use. The use of such approaches offers additional advantages of
mechanosynthesis over classical organic chemistry, in terms of
excellent selectivity and the possibility to perform previously
unknown reactions.14−16 Interestingly, an increasing number of
mechanochemical procedures for generating pharmaceutically
relevant fragments and functionalities have been reported thus
far.17−19 This novel mechanochemical application led to
coining the term “medicinal mechanochemistry.”20,21
We have recently developed a novel class of a potent and
selective 5-HT7 receptor (5-HT7R) antagonist, namely, an
arylsulfonamide derivative of (aryloxy)alkyl alicyclic amine,
and identified several lead structures that exhibit significant in
vivo antidepressant and pro-cognitive properties in rodents
(Figure 1).22−26
The classical “in batch” synthetic pathway of this class of
derivatives consists of four steps involving the alkylation of
commercially available phenols in biphasic conditions,
nucleophilic substitution of Boc-protected alicyclic amines,
removal of the protecting group, and sulfonylation of the
resulting primary amine in an alkaline environment (Scheme
1). The critical step of the entire process is the alkylation of
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Figure 1. Chemical structure of the potent and selective 5-HT7R
antagonist PZ-1361 belonging to the class of arylsulfonamides of
(aryloxy)alkyl alicyclic amines.
Scheme 1. In-Solution Synthesis of the Compound PZ-1361
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phenol, as this reaction should be performed in the presence of
a large excess of halogeno-alkanes (from 3 to 6 equiv) to avoid
unwanted dimerization or opening of the epoxide ring.
Additionally, apart from the deprotection of amine function,
column chromatography purification is required in all of the
remaining steps together with the use of a large amount of
organic solvents (in particular, the highly toxic dichloro-
methane).27,28 To overcome these issues and simultaneously
extend the concept of medicinal mechanochemistry, we
adapted the synthetic pathway by using a mechanochemical
approach for the synthesis of the potent and selective 5-HT7R
antagonist PZ-1361.29 To demonstrate the versatility of this
method, we subsequently increased the diversity of building
blocks by conducting experiments using 2-substituted phenols,
different central amine cores (e.g., piperazine, 3-amino-
tropane, 3-aminopyrrolidine), and differently substituted
arylsulfonyl chlorides. This allowed proposing mechanochem-
istry as a promising synthetic strategy in medicinal chemistry,
which would enable the preparation of lead compounds for
preclinical development in a more sustainable and greener
manner.30
The optimization of the synthetic pathway started with the
alkylation of commercially available 2-phenylphenol with
racemic epichlorohydrin (1 equiv). The reaction was initially
performed in a 10 mL PTFE jar with a 1 cm diameter stainless
steel ball by using a vibratory ball mill (vbm) operated at 30
Hz. A thorough study of the different parameters was
performed and is summarized in Table 1 (for more
information, see Tables S3−5).
Next, to investigate the kinetics of the alkylation, the
experiment was performed using potassium carbonate and
different time periods ranging from 40 to 220 min. A reaction
time of approximately 2 h was sufficient to obtain around 40%
conversion (Table 1, entry 5), while a prolonged milling time
slightly accelerated the formation of desired product 1a
without reaching full conversion (Table 1, entries 6 and 7).
Increasing the milling time promoted the formation of the
unwanted side products, 2a, resulting from nucleophilic
addiction of 2-phenylphenol to the oxirane derivative 1a. Of
note, a similar epoxide ring opening with carboxylic acids was
previously reported.31 On the basis of the assumption that
more energetic collisions might be achieved by increasing the
diameter of the milling ball, the use of a 1.5 cm diameter
stainless steel ball significantly improved the formation of the
monoalkylated product 1a, while restricting the formation of
2a to 2.5% (Table 1, entry 8). Additionally, the use of a slight
excess of epichlorohydrin (Table 1, entry 9) enabled to achieve
a 90% conversion of 2-phenylphenol into 1a (88% isolated
yield) without increasing the formation of 2a. After identifying
the optimal reaction conditions for alkylation on a small scale,
the influence of different substituents at the phenol was
subsequently determined using a 35 mL PTFE jar. The choice
of substituent (e.g., 2-isopropyl and 2-iodo) was based on the
biological data for this group of derivatives, wherein it was
confirmed that only compounds bearing a sterically hindered
substituent in 2-position preferentially bind to 5-HT7R.
23,24 All
of the tested substituted phenols showed higher conversion
rates under milling than the unsubstituted one, with the
following reactivity rank order: 2-Ph ≈ 2-I > 2-iPr > H (Table
2). These results are in line with yields and purities obtained
from the classical organic synthesis pathway using biphasic
conditions (for more information, see Supporting Informa-
tion).
Because the conversion rate was slightly lower than that
obtained in the 10 mL milling jar (Table 2, entry 1), ethyl
acetate and isopropanol as nontoxic liquid assistants were
evaluated to enhance the overall mixing and reaction
kinetics.32−36 The results showed that, regardless of the nature
of the phenol tested, liquid-assisted grinding (LAG) enabled to
increase the conversions into 1a−d up to 11%, while limiting
the formation of side products 2a−d, with isopropanol being
the best assistant. A simple basic extraction allowed to remove
Table 1. Optimization of Milling Conditions for the
Alkylation of 2-Phenylphenola
conversion (%)b
entry base (equiv) time (min) 1a 2a
1 Na2CO3 (3) 80 1 0
2 K2CO3 (3) 80 35 0
3 Cs2CO3 (3) 80 29 10
4 KOH (3) 80 36 10
5 K2CO3 (3) 140 43 2
6 K2CO3 (3) 180 48 5
7 K2CO3 (3) 220 52 10
8c K2CO3 (3) 140 61 2.5
9c,d K2CO3 (3) 140 90 2
aReaction conditions: 2-phenylphenol (1 equiv), epichlorohydrin (1
equiv), vbm 30 Hz, 10 mL PTFE jar, ϕball = 1 cm, total mass of
reagents = 100 mg. bConversions of 2-phenylphenol into 1a and 2a
were determined by UPLC/MS analysis. cThe ball used was 1.5 cm in
diameter. d1.2 equiv of epichlorohydrin was used.
Table 2. Effect of Liquid-Assisted Grinding on the
Alkylation of Different 2-Substituted Phenolsa
conversion (%)c
entry R additiveb 1a−d 2a−d % yield (1a−d)d
1 Ph 84 2 nde
2 Ph EtOAc 87 3 nde
3 Ph iPrOH 90 3 85
4 H 52 3 nde
5 H EtOAc 55 3 nde
6 H iPrOH 63 3 70
7 iPr 64 3 nde
8 iPr EtOAc 66 3 nde
9 iPr iPrOH 69 3 65
10 I 77 1 nde
11 I EtOAc 82 1 nde
12 I iPrOH 88 1 84
aReaction conditions: phenol (1 equiv), epichlorohydrin (1.2 equiv),
vbm 30 Hz, ϕball = 1.5 cm, time = 120−140 min, 35 mL PTFE jar;
total mass of reagents, 330 mg. b50 μL, η = 0.15 μL mg−1.
cConversions of 2-substituted phenols into 1a−d and 2a−d were
determined by UPLC/MS analysis. dIsolated yield of pure
compounds 1a−d. end = not determined.
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unreacted substrates and side products and afforded
intermediates 1a−d in high purity and yields (65−85%). As
a comparison, the same reactions performed in the solution for
48 h provided a higher amount of side products (20−35%),
which required column chromatography separation.
The next step involved the alkylation of Boc-4-amino-
piperidine with the [1,1′-biphenyl] oxirane derivative 1a in a
35 mL PTFE jar using vbm at 30 Hz (Scheme 2). This
reaction was originally performed in refluxing ethanol for 4 h,
with an excess of reagents and required purification on silica
gel (see Supporting Information). To our delight, the
mechanochemical approach resulted in a complete conversion
of the starting materials, reduced the reaction time to 70 min,
limited the amount of solvent (from 15 mL to 33 μL, η = 0.1
μL mg−1), avoided the excess of an alkylating agent, and
eliminated the purification step on silica gel. The desired
compound 3a was obtained in 90% yield (Scheme 2).
Encouraged by these findings, we extended this protocol to
the alkylation of amine function by testing different Boc-
protected alicyclic amines. The kinetics of the reaction strongly
depended on the type of amine used as the alkylation of 3-Boc-
amino-8-azabicyclooctane (tropane), and 4-Boc-piperazine
required a higher milling time (140 and 120 min, respectively)
to achieve high conversions. The corresponding intermediates
3b and 3c were isolated in 90% and 89% yields, respectively.
When 3-Boc-amino-pyrrolidine was used as a nucleophile, a
prolonged milling time afforded the desired compound 3d in
83% yield. However, 15% of the dehydrated byproduct 3e,
which was not generated in solution, was observed. In the case
of other alicyclic amines, a lower percentage of the respective
dehydrated side products (5−10%) were observed when the
milling time exceeded 160 min.
Various accessible methods to form a sulfonamide bond in
conventional solution or on solid support have been
extensively reported in literature.37−42 However, most of
them involve the use of a strong organic base, excess of a
sulfonylating agent, and low environmentally friendly solvents
(in particular dichloromethane). To develop a more
sustainable and efficient methodology, sulfonylation of
intermediate 4 with 3-chlorobenzenesulfonyl chloride was
optimized under milling conditions. Prior to the reaction,
primary amine 4 was obtained by the treatment of Boc-
derivative 3a in the presence of gaseous HCl (for more
information, see Supporting Information).
Compound PZ-1361 (5a) was finally isolated in a high yield
after milling of the substrates in the presence of nontoxic
K2CO3 for 1 min (Table 3, entry 1). To illustrate the versatility
of this mechanochemical approach, compounds 5b−e bearing
electron-withdrawing or -donating substituents in different
positions of the benzenesulfonamide moiety were prepared. It
seems that the position of the substituent has more influence
on sulfonylation rather than its electronic effect. All derivatives
were obtained in good yields and purities comparable to those
obtained in solution. In addition, the presence of a 2-fluoro or
3-methoxy substituent (Table 3, entries 3 and 4) led to higher
conversions in a relatively shorter time than 4-nitro and
unsubstituted analogues (Table 3, entries 2 and 5).
In summary, mechanochemistry enabled the preparation of
the biologically active compound PZ-1361 (5a) in 4 steps with
an overall yield of 64%. This approach required a total milling
time of 331 min; only a slight excess of the alkylating agent was
required, and no chromatographic purification was necessary
to isolate 5a in high purity (Figure 2). The versatility of the
protocol was confirmed by introducing diversification at the
aryloxy fragment (1a−d), central amine core (3a−d), and the
benzenesulfonamide moiety (5a−e). Compared to the classical
thermal methods in solution, the mechanochemical approach
offered several advantages including (i) improvement of the
overall yield (from 34% to 64%), (ii) reduction of reaction
time (from 60 to 5.5 h), and (iii) limitation of the use of toxic
solvents and the formation of byproducts. Moreover, reaction
conditions and workup procedures were simplified because
intermediates and final compounds were obtained by simple
extraction without the need for column chromatography
purification. To assess the sustainability of the newly developed
approach, the green chemistry metrics E factor and Ecoscale
Scheme 2. Mechanochemical Alkylation of Different Boc-
Protected Alicyclic Aminesa
aReaction conditions: vbm 30 Hz, ϕball = 1.5 cm, total mass of
reagents = 330 mg, 35 mL PTFE jar, EtOH (33 μL, η = 0.1 μL mg−1).
Table 3. Optimization of Milling Conditions for
Sulfonylation of Primary Aminea
entry R product time [min] % yieldb
1 3-Cl 5a 1 86
2 H 5b 5 87
3 2-F 5c 2 85
4 3-OMe 5d 3 86
5 4-NO2 5e 5 80
aReaction conditions: vbm 30 Hz, 35 mL PTFE jar, ϕball = 1.5 cm,
total mass of reagents = 330 mg. bAfter the addition of EtOAc and
washing with KHSO4 (aq).
Figure 2. In-solution vs solid-state synthesis of PZ-1361.
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score were calculated,43,44 which confirmed the advantage of
the mechanochemical strategy over the classical organic
chemistry pathway (for more information, see Supporting
Information). The E factor calculated for the 4-step synthesis
of PZ-1361 is reduced by 2.7 (from 1932 to 715) when
switching from classical solution synthesis to mechanochem-
istry.
In addition, Ecoscale scores were found to be excellent for
each synthetic step (>70) in the solid state, while some of
them were inadequate in solution (<50). To the best of our
knowledge, this approach represents the first example of
organic synthesis of a CNS-acting agent exclusively performed
using the mechanochemical methodology. Further studies
aimed to confirm the suitability of the mechanochemical
approach for an efficient and sustainable synthesis of a focused
library of biologically active compounds are under develop-
ment.
■ EXPERIMENTAL SECTION
General Remarks. The milling treatments were carried out in a
vibratory ball-mill Retsch MM400 operated at 30 Hz. The milling
load is defined as the sum of the mass of the reactants per free volume
in the jar and was equal to 10 or 25 mg/mL. All of the reactions using
vibratory ball mill were performed under air. 1H and 13C NMR
spectra were recorded on a JEOL JNM-ECZR500 RS1 (ECZR
version) at 500 and 126 MHz, respectively, and are reported in ppm
using deuterated solvent for calibration (CDCl3 or CD3OD-d4). The J
values are reported in hertz (Hz), and the splitting patterns are
designated as follows: br s. (broad singlet), br d. (broad doublet), s
(singlet), d (doublet), t (triplet), q (quartet), dd (doublet of
doublets), dt (doublet of triplets), td (triplet of doublets), tt (triplet
of triplets), m (multiplet). Mass spectra were recorded on a UPLC-
MS/MS system consisting of a Waters ACQUITY UPLC (Waters
Corporation, Milford, MA, USA) coupled to a Waters TQD mass
spectrometer (electrospray ionization mode ESI-tandem quadrupole).
Chromatographic separations were carried out using the Acquity
UPLC BEH (bridged ethyl hybrid) C18 column; 2.1 mm × 100 mm,
and 1.7 μm particle size, equipped with Acquity UPLC BEH C18 Van
Guard precolumn; 2.1 mm × 5 mm, and 1.7 μm particle size. The
column was maintained at 40 °C and eluted under gradient conditions
from 95% to 0% of eluent A over 10 min, at a flow rate of 0.3 mL
min−1. Eluent A: water/formic acid (0.1%, v/v), Eluent B:
acetonitrile/formic acid (0.1%, v/v). HRMS analyses were performed
on an UPLC Acquity H-Class from Waters hyphenated to a Synapt
G2-S mass spectrometer with a dual ESI source from Waters.
Alkylation of 2-Phenylphenol in Ball Mill (General
Procedure A). 2-Phenylphenol (24.5 mg, 0.144 mmol, 1 equiv)
and previously grinded K2CO3 (59.58 mg, 0.431 mmol, 3.0 equiv)
were introduced in a 10 mL PTFE jar (milling load 10 mg/mL) with
one stainless steel ball (ϕball = 1.5 cm) followed by the addition of
epichlorohydrin (13.5 μL, 0.172 mmol, 1.2 equiv). The reaction was
carried out for 120−140 min at rt. The mixture was then solubilized
in CH2Cl2 (15 mL), and the organic phase was washed with 2 N
NaOH aqueous solution (3 × 5 mL) and saturated NaCl solution (1
× 5 mL), dried over Na2SO4, and finally filtered and concentrated
under reduced pressure, yielding intermediate 1a as a white powder
(29.0 mg, yield 88%).
Alkylation of Phenol in Ball Mill (General Procedure B).
Different substituted phenol (1 equiv) and previously grinded K2CO3
(3 equiv) were introduced in a 35 mL PTFE jar (milling load 10 mg/
mL) with one stainless steel ball (ϕball = 1.5 cm). Then
epichlorohydrin (1.2 equiv) was added. The reaction was carried
out for 120−140 min at rt. The mixture was solubilized in CH2Cl2
(15 mL), and the organic phase was washed with 2 N NaOH aqueous
solution (3 × 5 mL) and saturated NaCl solution (1 × 5 mL), dried
over Na2SO4, and finally filtered and concentrated under reduced
pressure.
2-(([1,1′-Biphenyl]-2-yloxy)methyl)oxirane (1a) [CAS 7144-
65-2]. General Procedure B was followed with 2-phenylphenol (80.7
mg, 0.474 mmol, 1 equiv), previously grinded K2CO3 (196.6 mg, 1.42
mmol, 3 equiv), epichlorohydrin (44.6 μL, 0.569 mmol, 1.2 equiv),
and 2-propanol (50 μL, η = 0.15 μL mg−1) to afford intermediate 1a
as a white powder (81 mg, yield 85%).
C15H14O2, MW: 226.27. Monoisotopic mass: 226.10. UPLC/MS:
tR = 7.20 min, purity = 99%, [M + MeCN + H]
+ 268.1. 1H NMR
(500 MHz, CDCl3): δ 7.58 (dt, J = 8.0, 1.1 Hz, 1H), 7.55−7.60 (m,
1H), 7.41−7.46 (m, 2H), 7.34−7.38 (m, 2H), 7.32 (td, J = 8.0, 1.7
Hz, 1H), 7.08 (td, J = 7.4, 1.1 Hz, 1H), 6.98−7.03 (m, 1H), 4.22 (dd,
J = 11.5, 2.9 Hz, 1H), 3.99 (dd, J = 10.9, 5.2 Hz, 1H), 3.25−3.29 (m,
1H), 2.81 (t, J = 4.6 Hz, 1H), 2.68 (dd, J = 5.2, 2.9 Hz, 1H). 13C{1H}
NMR (126 MHz, CDCl3): δ 155.5, 138.4, 131.4, 131.2, 129.7, 128.7,
128.1, 127.1, 121.8, 113.3, 69.1, 50.4, 44.7. HRMS (ESI-TOF): m/z
[M + MeCN + H]+ calcd for C17H18NO2, 268.1338; found, 268.1346.
Data in agreement with lit.29
2-(([1,1′-Biphenyl]-2-yloxy)methyl)oxirane (1a) [CAS 7144-
65-2] (Synthesis on a mmol Scale). 2-Phenylphenol (195.7 mg,
1.15 mmol, 1 equiv) and previously grinded K2CO3 (476.7 mg, 3.45
mmol, 3.0 equiv) were introduced in a 35 mL PTFE jar (milling load
25 mg/mL) with one stainless steel ball (ϕball = 1.5 cm) followed by
the addition of epichlorohydrin (108.2 μL, 1.38 mmol, 1.2 equiv).
The reaction was carried out for 140 min at rt. The mixture was then
solubilized in CH2Cl2 (25 mL), and the organic phase was washed
with 2 N NaOH aqueous solution (3 × 10 mL) and saturated NaCl
solution (1 × 10 mL), dried over Na2SO4, and finally filtered and
concentrated under reduced pressure, yielding intermediate 1a as a
white powder (215.8 mg, yield 83%).
2-(Phenoxymethyl)oxirane (1b) [CAS 122-60-1]. General
Procedure B was followed with phenol (50.1 mg, 0.532 mmol, 1
equiv), previously grinded K2CO3 (220.8 mg, 1.597 mmol, 3 equiv),
epichlorohydrin (50.1 μL, 0.639 mmol, 1.2 equiv), and 2-propanol
(50 μL, η = 0.15 μL mg−1) to afford intermediate 1b as a white
powder (55 mg, yield 70%).
C9H10O2, MW: 150.17. Monoisotopic mass: 150.07. UPLC/MS: tR
= 5.44 min, purity = 97%, [M + MeCN + H]+ 192.1. 1H NMR (500
MHz, CDCl3): δ 7.30 (tt, J = 8.6, 1.7 Hz, 2H), 6.96−7.01 (m, 1H),
6.91−6.95 (m, 2H), 4.20 (dd, J = 11.2, 3.2 Hz, 1H), 3.90 (dd, J =
10.9, 5.7 Hz, 1H), 3.30−3.35 (m, 1H), 2.84−2.88 (m, 1H), 2.72 (dd,
J = 4.9, 2.6 Hz, 1H). 13C{1H} NMR (126 MHz, CDCl3): δ 158.6,
129.7, 121.3, 114.8, 68.8, 50.3, 44.7. HRMS (ESI-TOF): m/z [M +
MeCN + H]+ calcd for C11H14NO2, 192.1025; found, 192.1032. Data
in agreement with lit.45
2-((2-Isopropylphenoxy)methyl)oxirane (1c) [CAS 5904-89-
2]. General Procedure B was followed with 2-isopropylphenol (65.2
mg, 0.479 mmol, 1 equiv), previously grinded K2CO3 (198.4 mg,
1.436 mmol, 3 equiv), epichlorohydrin (45.1 μL, 0.575 mmol, 1.2
equiv), and 2-propanol (50 μL, η = 0.15 μL mg−1) to afford
intermediate 1c as a colorless oil (59.8 mg, yield 65%).
C12H16O2, MW: 192.25. Monoisotopic mass: 192.12. UPLC/MS:
tR = 7.33 min, purity = 100%, [M + MeCN + H]
+ 234.2. 1H NMR
(500 MHz, CDCl3): δ 7.25−7.29 (m, 1H), 7.18 (td, J = 7.4, 1.7 Hz,
1H), 6.99 (t, J = 7.4 Hz, 1H), 6.86 (d, J = 8.0 Hz, 1H), 4.26 (dd, J =
10.9, 2.9 Hz, 1H), 4.00 (dd, J = 10.9, 5.2 Hz, 1H), 3.37−3.45 (m,
2H), 2.92 (dd, J = 5.2, 4.0 Hz, 1H), 2.80 (dd, J = 4.9, 2.6 Hz, 1H),
1.29 (dd, J = 6.9, 1.1 Hz, 6H). 13C{1H} NMR (126 MHz, CDCl3): δ
155.8, 137.4, 126.7, 126.4, 121.4, 111.7, 68.9, 50.5, 44.7, 27.0, 22.9.
HRMS (ESI-TOF): m/z [M + MeCN + H]+ calcd for C14H20NO2,
234.1494; found, 234.1502. Data in agreement with lit.29
2-((2-Iodophenoxy)methyl)oxirane (1d) [CAS 75746-33-7].
General Procedure B was followed with 2-iodophenol (93.9 mg, 0.427
mmol, 1 equiv), previously grinded K2CO3 (176.9 mg, 1.28 mmol, 3
equiv), epichlorohydrin (40.1 μL, 0.512 mmol, 1.2 equiv), and 2-
propanol (50 μL, η = 0.15 μL mg−1) to afford intermediate 1d as a
white powder (100 mg, yield 84%).
C9H9IO2, MW: 276.07. Monoisotopic mass: 275.96. UPLC/MS: tR
= 6.49 min, purity = 99%, [M + MeCN + H]+ 318.0. 1H NMR (500
MHz, CDCl3): δ 7.71 (dd, J = 8.0, 1.7 Hz, 1H), 7.22 (td, J = 7.7, 1.7
Hz, 1H), 6.76 (dd, J = 8.3, 1.4 Hz, 1H), 6.67 (td, J = 8.0, 1.1 Hz, 1H),
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4.28 (dd, J = 11.5, 2.9 Hz, 1H), 3.93 (dd, J = 10.9, 5.2 Hz, 1H), 3.29−
3.33 (m, 1H), 2.80−2.85 (m, 2H). 13C{1H} NMR (126 MHz,
CDCl3): δ 157.1, 139.7, 129.8, 123.3, 112.8, 86.8, 69.5, 50.0, 44.8.
HRMS (ESI-TOF): m/z [M + MeCN + H]+ calcd for C11H13INO2,
317.9991; found, 317.9998. Data in agreement with lit.46
Alkylation of Boc-N-Protected Alicyclic Amines (General
Procedure C). Intermediate 1a (1 equiv) and Boc-protected alicyclic
amine (1 equiv) were introduced in a 35 mL PTFE jar (milling load
10 mg/mL) with one stainless steel ball (ϕball = 1.5 cm), followed by
the addition of EtOH (33 μL, η = 0.1 μL mg−1) as a liquid assistant.
The reaction was carried out for 70−160 min at rt. Then, the product
was solubilized in ethyl acetate (20 mL), and the organic phase was
washed with KHSO4 aqueous solution at pH = 3.5 (3 × 7 mL) and
saturated NaCl solution (1 × 7 mL), dried over Na2SO4, and finally
filtered and concentrated under reduced pressure.
tert-Butyl ((1-(3-([1,1′-Biphenyl]-2-yloxy)-2-hydroxy
propyl)piperidin-4-yl)carbamate (3a) [CAS 2095849-45-7].
General Procedure C was followed with compound 1a (175.1 mg,
0.774 mmol, 1 equiv), 4-Boc-amino-piperidine (154.9 mg, 0.774
mmol, 1 equiv), and EtOH (33 μL, η = 0.1 μL mg−1) to afford
intermediate 3a as a white powder (297 mg, yield 90%). C25H34N2O4,
MW: 426.55. Monoisotopic mass: 426.25. UPLC/MS: tR = 5.46 min,
purity = 97%, [M + H]+ 427.3. 1H NMR (500 MHz, CDCl3): δ 7.47
(d, J = 7.4 Hz, 2H), 7.27−7.41 (m, 5H), 7.05 (t, J = 7.4 Hz, 1H),
6.94−6.98 (m, 1H), 4.51 (br s, 1H), 4.13 (br s, 1H), 3.97−4.10 (m,
1H), 3.88 (t, J = 7.4 Hz, 1H), 3.42−3.58 (m, 2H), 2.86−3.10 (m,
2H), 2.50−2.65 (m, 2H), 2.44 (t, J = 11.5 Hz, 1H), 2.05−2.25 (m,
1H), 1.87−2.05 (m, 2H), 1.62−1.76 (m, 2H), 1.43 (s, 9H). 13C{1H}
NMR (126 MHz, CDCl3): δ 155.2, 138.6, 131.3, 130.9, 129.8, 128.9,
128.0, 127.0, 121.8, 113.2, 79.8, 70.4, 65.4, 61.6, 51.7, 31.1, 29.8, 28.5.
HRMS (ESI-TOF): m/z [M + H]+ calcd for C25H35N2O4, 427.2591;
found, 427.2601. Data in agreement with lit.29
tert-Butyl ((1-(3-([1,1′-Biphenyl]-2-yloxy)-2-hydroxy
propyl)piperidin-4-yl)carbamate (3a) [CAS 2095849-45-7]
(Synthesis on a mmol Scale). Intermediate 1a (424.5 mg, 1.88
mmol, 1 equiv) and Boc-N-4-aminopiperidine (375.5 mg, 1.88 mmol,
1 equiv) were introduced in a 35 mL PTFE jar (milling load 25 mg/
mL) with one stainless steel ball (ϕball = 1.5 cm) followed by the
addition of EtOH (80 μL, η = 0.1 μL mg−1) as a liquid assistant. The
reaction was carried out for 70 min at rt. Then, the product was
solubilized in ethyl acetate (30 mL), and the organic phase was
washed with KHSO4 aqueous solution at pH = 3.5 (3 × 10 mL) and
saturated NaCl solution (1 × 10 mL), dried over Na2SO4, and finally
filtered and concentrated under reduced pressure, yielding inter-
mediate 3a as a white powder (704.3 mg, yield 88%).
tert-Butyl ((1R,5S)-8-(3-([1,1′-Biphenyl]-2-yloxy)-2-hydroxy-
propyl)-8-azabicyclo[3.2.1]octan-3-yl)carbamate (3b). General
Procedure C was followed with compound 1a (165.0 mg, 0.729
mmol, 1 equiv), 3-Boc-amino-tropane (165.0 mg, 0.729 mmol, 1
equiv), and EtOH (33 μL, η = 0.1 μL mg−1) to afford intermediate 3b
as a white powder (302.6 mg, yield 90%).
C27H36N2O4, MW: 452.59. Monoisotopic mass: 452.27. UPLC/
MS: tR = 5.73 min, purity = 95%, [M + H]
+ 453.3. 1H NMR (500
MHz, CDCl3): δ 7.43−7.49 (m, 2H), 7.33−7.38 (m, 2H), 7.27−7.32
(m, 3H), 7.04 (t, J = 6.9 Hz, 1H), 6.94−6.98 (m, 1H), 4.53 (br d, J =
7.4 Hz, 1H), 4.17 (br s, 1H), 4.08−4.14 (m, 1H), 3.82−3.89 (m, 1H),
3.75−3.81 (m, 1H), 3.41−3.46 (m, 1H), 3.31−3.37 (m, 1H), 2.65 (d,
J = 12.6 Hz, 1H), 2.40−2.61 (m, 1H), 1.73−1.95 (m, 5H), 1.60−1.71
(m, 2H), 1.39−1.46 (m, 9H), 0.75−0.91 (m, 2H). 13C{1H} NMR
(126 MHz, CDCl3): δ 155.4, 155.1, 138.6, 131.1, 130.9, 129.7, 128.9,
127.9, 127.1, 121.7, 112.8, 79.7, 69.7, 66.1, 62.7, 60.9, 56.5, 41.3, 36.9,
29.8, 29.7, 28.5, 25.9, 25.2. HRMS (ESI-TOF): m/z [M + H]+ calcd
for C27H37N2O4, 453.2753; found, 453.2760.
tert-Butyl (4-(3-([1,1′-Biphenyl]-2-yloxy)-2-hydroxy propyl)-
piperazine-1-carboxylate (3c). General Procedure C was followed
with compound 1a (181.0 mg, 0.800 mmol, 1 equiv), Boc-piperazine
(149.0 mg, 0.800 mmol, 1 equiv), and EtOH (33 μL, η = 0.1 μL
mg−1) to afford intermediate 3c as a white powder (292.2 mg, yield
89%).
C24H32N2O4, MW: 412.52. Monoisotopic mass: 412.24. UPLC/
MS: tR = 5.4 min, purity = 97%, [M + H]
+ 413.2.
1H NMR (500 MHz, CDCl3): δ 7.48−7.53 (m, 2H), 7.35−7.41
(m, 2H), 7.27−7.34 (m, 3H), 7.04 (td, J = 7.4, 1.1 Hz, 1H), 6.98 (d, J
= 8.0 Hz, 1H), 3.92−4.02 (m, 3H), 3.35−3.43 (m, 4H), 2.93 (br s,
1H), 2.41−2.52 (m, 4H), 2.25−2.32 (m, 2H), 1.46 (s, 9H). 13C{1H}
NMR (126 MHz, CDCl3): δ 155.6, 154.8, 138.5, 131.4, 130.9, 129.7,
128.8, 128.0, 127.0, 121.6, 113.2, 79.9, 71.0, 65.9, 60.9, 53.3, 28.5.
HRMS (ESI-TOF): m/z [M + H]+ calcd for C24H33N2O4, 413.2440;
found, 413.2446.
tert-Butyl ((1-(3-([1,1′-Biphenyl]-2-yloxy)-2-hydroxy
propyl)pyrrolidin-3-yl)carbamate (3d). General Procedure C
was followed with compound 1a (181.0 mg, 0.800 mmol, 1 equiv),
3-Boc-amino-pyrrolidine (149.0 mg, 0.800 mmol, 1 equiv), and EtOH
(33 μL, η = 0.1 μL mg−1) to afford intermediate 3d as a white powder
(268.7 mg, yield 83%). In this case, crystallization in EtOH was
required to obtain the pure compound.
C24H32N2O4, MW: 412.52. Monoisotopic mass: 412.24. UPLC/
MS: tR = 5.52 min, purity = 95%, [M + H]
+ 413.2.
1H NMR (500 MHz, CDCl3): δ 7.50 (d, J = 7.6 Hz, 2H), 7.35−
7.40 (m, 2H), 7.32 (dd, J = 7.4, 1.7 Hz, 1H), 7.26−7.30 (m, 2H), 7.03
(td, J = 7.4, 1.1 Hz, 1H), 6.94−7.00 (m, 1H), 5.05−5.13 (m, 1H),
4.09−4.17 (m, 1H), 3.13−3.42 (m, 1H), 2.80−2.89 (m, 1H), 2.67−
2.75 (m, 1H), 2.55−2.64 (m, 2H), 2.42−2.52 (m, 1H), 2.34−2.40
(m, 1H), 2.28−2.34 (m, 1H), 2.11−2.23 (m, 2H), 1.48−1.60 (m,
1H), 1.43 (s, 9H). 13C{1H} NMR (126 MHz, CDCl3): δ 155.6,
155.5, 138.5, 131.3, 130.9, 129.7, 128.8, 128.0, 127.0, 121.6, 113.3,
79.3, 71.2, 71.2, 67.7, 61.7, 61.1, 58.8, 52.8, 49.8, 32.6, 28.5. HRMS
(ESI-TOF): m/z [M + H]+ calcd for C24H33N2O4, 413.2440; found,
413.2446.
Deprotection of Boc Function in Solid State (General
Procedure D). Intermediate 3a (0.5 g, 1.16 mmol) was submitted to
HClgas for 2 h at rt to afford the primary amine 4 as a white
hydrochloride salt (0.41 g, yield 98%).
1-([1,1′-Biphenyl]-2-yloxy)-3-(4-aminopiperidin-1-yl) prop-
an-2-ol (4). White powder (0.41 g, yield 98%). C20H26N2O2·HCl,
MW: 362.90. Monoisotopic mass: 326.43. UPLC/MS: tR = 3.62 min,
purity = 100%, [M + H]+ 327.2. 1H NMR (500 MHz, CD3OD): δ
7.46−7.51 (m, 2H), 7.38−7.44 (m, 2H), 7.29−7.33 (m, 2H), 7.25−
7.28 (m, 1H), 7.07 (d, J = 8.2 Hz, 1H), 7.01−7.05 (m, 1H), 4.30−
4.36 (m, 1H), 4.04 (dd, J = 9.9, 4.4 Hz, 1H), 3.97 (dd, J = 9.7, 5.6 Hz,
1H), 3.58 (q, J = 7.0 Hz, 2H), 3.44−3.53 (m, 1H), 3.09−3.19 (m,
3H), 2.18−2.28 (m, 2H), 1.96−2.12 (m, 2H), 1.12−1.18 (m, 4H).
13C{1H} NMR (126 MHz, CD3OD): δ 155.4, 138.6, 131.3, 130.5,
129.5, 128.7, 127.9, 126.9, 121.7, 113.4, 70.6, 64.2, 57.0, 50.4, 45.3,
17.2. HRMS (ESI-TOF): m/z [M + H]+ calcd for C20H27N2O2,
327.2073; found, 327.2079.
Sulfonylation of Primary Amine (General Procedure E).
Intermediate 4 (1 equiv), selected benzenesulfonyl chloride (1 equiv),
and previously grinded K2CO3 (1 equiv) were introduced in a 35 mL
PTFE jar (milling load 10 mg/mL) with one stainless steel ball (ϕball
= 1.5 cm). The reaction was carried out for 1−5 min at rt. Then, the
crude mixture was solubilized in ethyl acetate (20 mL), and the
organic phase was washed with KHSO4 aqueous solution at pH = 3.5
(3 × 7 mL), saturated NaCl solution (1 × 7 mL), dried over Na2SO4,
and finally filtered and concentrated under a vacuum.
3-Chloro-N-(1-(3-([1,1′-biphenyl]-2-yloxy)-2-hydroxy
propyl)piperidin-4-yl)-benzenesulfonamide PZ-1361 (5a)
[CAS 2095849-69-5]. General Procedure E was followed with
primary amine 4 (168.2 mg, 0.463 mmol, 1 equiv), 3-chloro-
benzenesulfonyl chloride (65.24 μL, 0.463 mmol, 1 equiv), and
previously grinded K2CO3 (64.0 mg, 0.463, 1 equiv) to afford final
compound 5a as a white powder (200.1 mg, yield 86%).
C26H29ClN2O4S, MW: 501.04. Monoisotopic mass: 500.15.
UPLC/MS: tR = 5.89 min, purity = 98%, [M + H]
+ 501.2.
1H NMR (500 MHz, CDCl3): δ 7.89 (t, J = 1.9 Hz, 1H), 7.77 (dt, J
= 7.7, 0.9 Hz, 1H), 7.53 (dq, J = 8.0, 0.9 Hz, 1H), 7.50 (dt, J = 8.3, 1.4
Hz, 2H), 7.43 (t, J = 8.0 Hz, 1H), 7.36−7.39 (m, 2H), 7.26−7.33 (m,
3H), 7.03 (td, J = 7.5, 1.0 Hz, 1H), 6.96 (dd, J = 8.2, 0.7 Hz, 1H),
5.27 (s, 1H), 3.84−4.00 (m, 3H), 3.16 (spt, J = 4.3 Hz, 1H), 2.72−
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2.78 (m, 1H), 2.56−2.62 (m, 1H), 2.34−2.40 (m, 1H), 2.30 (dd, J =
15.0, 3.8 Hz, 1H), 2.16−2.23 (m, 1H), 1.91−1.99 (m, 1H), 1.68−
1.76 (m, 2H), 1.39−1.52 (m, 2H). 13C{1H} NMR (126 MHz,
CDCl3): δ 155.6, 143.2, 138.5, 135.3, 132.8, 131.3, 130.9, 130.6,
129.7, 128.8, 127.9, 127.1, 127.0, 126.1, 121.6, 113.2, 70.9, 66.0, 60.5,
53.2, 51.3, 50.8, 33.0, 32.9, 29.7. HRMS (ESI-TOF): m/z [M + H]+




[CAS 2095849-69-5] (Synthesis on a mmol Scale). Intermediate
4 (407.7 mg, 1.12 mmol, 1 equiv), 3-chlorobenzenesulfonyl chloride
(158.2 μL, 1.12 mmol, 1 equiv), and previously grinded K2CO3
(155.3 mg, 1.12 mmol, 1 equiv) were introduced in a 35 mL PTFE jar
(milling load 25 mg/mL) with one stainless steel ball (ϕball = 1.5 cm).
The reaction was carried out for 1 min at rt. Then, the crude mixture
was solubilized in ethyl acetate (25 mL), and the organic phase was
washed with KHSO4 aqueous solution at pH = 3.5 (3 × 10 mL) and
saturated NaCl solution (1 × 10 mL), dried over Na2SO4, and finally
filtered and concentrated under a vacuum, yielding compound 5a as a
white powder (472.2 mg, yield 84%).
N-(1-(3-([1,1′-Biphenyl]-2-yloxy)-2-hydroxypropyl)-
piperidin-4-yl)benzenesulfonamide (5b). General Procedure E
was followed with primary amine 4 (176.7 mg, 0.487 mmol, 1 equiv),
benzenesulfonyl chloride (62.14 μL, 0.487 mmol, 1 equiv), and
previously grinded K2CO3 (67.3 mg, 0.487 mmol, 1 equiv) to afford
final compound 5b as a colorless oil (197.4 mg yield 87%).
C26H30N2O4S, MW: 466.59. Monoisotopic mass: 466.19. UPLC/
MS: tR = 5.23 min, purity = 98%, [M + H]
+ 467.2. 1H NMR (500
MHz, CDCl3): δ 7.87−7.90 (m, 2H), 7.56 (tt, J = 6.3, 1.4 Hz, 1H),
7.47−7.52 (m, 4H), 7.33−7.39 (m, 2H), 7.26−7.32 (m, 3H), 7.03
(td, J = 7.5, 1.0 Hz, 1H), 6.96 (dd, J = 8.3, 0.9 Hz, 1H), 5.28 (s, 1H),
5.04 (br. s, 1H), 3.86−3.94 (m, 3H), 3.15 (spt, J = 4.3 Hz, 1H), 2.74
(d, J = 11.5 Hz, 1H), 2.58 (d, J = 11.2 Hz, 1H), 2.36 (dd, J = 12.3, 8.6
Hz, 1H), 2.29 (dd, J = 12.6, 4.0 Hz, 1H), 2.19 (t, J = 10.2 Hz, 1H),
1.95 (t, J = 10.6 Hz, 1H), 1.67−1.75 (m, 2H), 1.36−1.50 (m, 2H).
13C{1H} NMR (126 MHz, CDCl3): δ 155.6, 141.3, 138.5, 132.7,
131.3, 130.9, 129.7, 129.2, 128.8, 128.0, 126.9, 121.6, 113.2, 70.9,
66.0, 60.5, 51.3, 50.6, 33.0, 32.9. HRMS (ESI-TOF): m/z [M + H]+
calcd for C26H31N2O4S, 467.2005; found, 467.2007.
2-Fluoro-N-(1-(3-([1,1′-biphenyl]-2-yloxy)-2-hydroxy
propyl)piperidin-4-yl)-benzenesulfonamide (5c). General Pro-
cedure E was followed with primary amine 4 (172.1 mg, 0.474 mmol,
1 equiv), 2-fluoro-benzenesulfonyl chloride (62.80 μL, 0.474 mmol, 1
equiv), and previously grinded K2CO3 (65.6 mg, 0.474 mmol, 1
equiv) to afford final compound 5c as a white powder (190.5 mg,
yield 85%).
C26H29FN2O4S, MW: 484.58. Monoisotopic mass: 484.18. UPLC/
MS: tR = 5.35 min, purity = 97%, [M + H]
+ 485.2. 1H NMR (500
MHz, CDCl3): δ 7.91 (td, J = 7.6, 1.7 Hz, 1H), 7.52−7.58 (m, 1H),
7.50 (dt, J = 6.9, 1.4 Hz, 1H), 7.34−7.39 (m, 2H), 7.23−7.33 (m,
4H), 7.15−7.21 (m, 1H), 7.03 (td, J = 7.5, 1.0 Hz, 1H), 6.97 (dd, J =
8.3, 0.9 Hz, 1H), 5.23−5.28 (m, 1H), 3.86−3.95 (m, 3H), 3.23 (spt, J
= 4.8 Hz, 1H), 2.74 (d, J = 11.7 Hz, 1H), 2.58 (d, J = 12.0 Hz, 1H),
2.37 (dd, J = 12.0, 8.0 Hz, 1H), 2.30 (dd, J = 12.0, 4.0 Hz, 1H), 2.18
(t, J = 10.5 Hz, 1H), 1.94 (t, J = 10.7 Hz, 1H), 1.68−1.76 (m, 2H),
1.40−1.54 (m, 2H). 13C{1H} NMR (126 MHz, CDCl3): δ 158.8 (d, J
= 254.1 Hz), 155.7, 138.5, 135.1, 135.0, 131.2, 130.9, 130.1, 129.7,
128.8, 127.9, 127.0, 124.7, 124.6, 121.6, 117.2, 117.0, 113.2, 70.9,
66.1, 60.5, 53.2, 51.4, 50.9, 32.9, 32.8. HRMS (ESI-TOF): m/z [M +
H]+ calcd for C26H30FN2O4S, 485.1910; found, 485.1914.
3 -Methoxy -N - ( 1 - (3 - ( [ 1 ,1 ′ -b ipheny l ] -2 -y loxy ) -2 -
hydroxypropyl)piperidin-4-yl)-benzenesulfonamide (5d).
General Procedure E was followed with primary amine 4 (169.2
mg, 0.466 mmol, 1 equiv), 3-methoxybenzenesulfonyl chloride (65.99
μL, 0.466 mmol, 1 equiv), and previously grinded K2CO3 (64.4 mg,
0.466 mmol, 1 equiv) to afford final compound 5d as a white powder
(190.5 mg, yield 86%).
C27H32N2O5S, MW: 496.62. Monoisotopic mass: 496.2. UPLC/
MS: tR = 5.45 min, purity = 95%, [M + H]
+ 497.2. 1H NMR (500
MHz, CDCl3): δ 7.48−7.51 (m, 2H), 7.45−7.48 (m, 1H), 7.43 (t, J =
2.0 Hz, 1H), 7.40 (d, J = 8.3 Hz, 1H), 7.34−7.38 (m, 2H), 7.26−7.33
(m, 3H), 7.08 (ddd, J = 8.0, 2.6, 0.6 Hz, 1H), 7.03 (td, J = 7.4, 1.1 Hz,
1H), 6.96 (d, J = 8.3 Hz, 1H), 5.27 (s, 1H), 3.87−3.95 (m, 3H), 3.83
(s, 3H), 3.11−3.19 (m, 1H), 2.74 (d, J = 11.2 Hz, 1H), 2.57 (d, J =
11.2 Hz, 1H), 2.36 (dd, J = 12.6, 8.9 Hz, 1H), 2.29 (dd, J = 12.9, 4.0
Hz, 1H), 2.19 (t, J = 10.2 Hz, 1H), 1.94 (t, J = 10.5 Hz, 1H), 1.72
(dd, J = 8.7, 3.9 Hz, 2H), 1.37−1.52 (m, 2H). 13C{1H} NMR (126
MHz, CDCl3): δ 160.0, 155.6, 142.5, 138.5, 131.2, 130.9, 130.3,
129.7, 128.8, 128.0, 127.0, 121.6, 119.1, 119.0, 113.2, 111.8, 70.9,
66.0, 60.5, 55.8, 53.6, 51.4, 50.7, 33.0, 32.8. HRMS (ESI-TOF): m/z
[M + H]+ calcd for C27H33N2O5S, 497.2110; found, 497.2115.
4-Nitro-N-(1-(3-([1,1′-biphenyl]-2-yloxy)-2-hydroxy propyl)-
piperidin-4-yl)-benzenesulfonamide (5e). General Procedure E
was followed with primary amine 4 (165.7 mg, 0.457 mmol, 1 equiv),
4-nitrobenzenesulfonyl chloride (101.2 mg, 0.457 mmol, 1 equiv),
and previously grinded K2CO3 (63.1 mg, 0.457 mmol, 1 equiv) to
afford final compound 5e as a yellow powder (187.1 mg, yield 80%).
C26H29N3O6S, MW: 511.59. Monoisotopic mass: 511.18. UPLC/
MS: tR = 5.67 min, purity 96%, [M + H]
+ 512.2. 1H NMR (500 MHz,
CDCl3): δ 8.27−8.33 (m, 2H), 8.01−8.07 (m, 2H), 7.46−7.53 (m,
2H), 7.33−7.38 (m, 2H), 7.24−7.33 (m, 3H), 7.00−7.06 (m, 1H),
6.95 (d, J = 7.7 Hz, 1H), 5.26−5.29 (m, 1H), 3.93−3.98 (m, 1H),
3.86−3.93 (m, 2H), 3.14−3.23 (m, 1H), 2.77 (d, J = 11.2 Hz, 1H),
2.61 (d, J = 11.2 Hz, 1H), 2.34−2.44 (m, 1H), 2.30 (dd, J = 12.6, 2.9
Hz, 1H), 2.19 (t, J = 11.2 Hz, 1H), 1.95 (t, J = 11.2 Hz, 1H), 1.67−
1.75 (m, 2H), 1.37−1.52 (m, 2H). 13C{1H} NMR (126 MHz,
CDCl3): δ 155.6, 150.0, 147.4, 138.4, 131.2, 131.0, 129.7, 128.8,
128.2, 128.0, 127.0, 124.6, 121.7, 113.2, 70.8, 66.1, 60.3, 53.6, 51.3,
51.1, 33.2, 33.0. HRMS (ESI-TOF): m/z [M + H]+ calcd for
C26H30N3O6S, 512.1855; found, 512.1863.
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Chmielarz, P.; Kusḿierczyk, J.; Bojarski, A. J.; Popik, P. Novel multi-
target azinesulfonamides of cyclic amine derivatives as potential
antipsychotics with pro-social and pro-cognitive effects. Eur. J. Med.
Chem. 2018, 145, 790−804.
(42) Tsai, A. S.; Curto, J. M.; Rocke, B. N.; Dechert-Schmitt, A. M.
R.; Ingle, G. K.; Mascitti, V. One-step synthesis of sulfonamides from
N-tosylhydrazones. Org. Lett. 2016, 18, 508−511.
(43) Roschangar, F.; Sheldon, R. A.; Senanayake, C. H. Overcoming
barriers to green chemistry in the pharmaceutical industry - the Green
Aspiration Level concept. Green Chem. 2015, 17, 752−768.
(44) Van Aken, K.; Strekowski, L.; Patiny, L. EcoScale, a semi-
quantitative tool to select an organic preparation based on economical
and ecological parameters. Beilstein J. Org. Chem. 2006, 2, 3.
(45) Clarkson, C.; Musonda, C. C.; Chibale, K.; Campbell, W. E.;
Smith, P. J. Synthesis of totarol amino alcohol derivatives and their
antiplasmodial activity and cytotoxicity. Bioorg. Med. Chem. 2003, 11,
4417−4422.
(46) Liu, Y.; Bao, W. Copper-catalyzed tandem process: an efficient
approach to 2-substituted-1,4-benzodioxanes. Org. Biomol. Chem.
2010, 8, 2700−2703.
The Journal of Organic Chemistry pubs.acs.org/joc Note
https://dx.doi.org/10.1021/acs.joc.0c01044
J. Org. Chem. 2020, 85, 10958−10965
10965
